Your search returned 3 results.

Results
	1.	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects. [electronic resource] by Wan, Hong Gumbiner, Barry Joh, Tenshang Riel, Tom Udata, Chandrasekhar Forgues, Philippe Garzone, Pamela D Producer: 20180515 In: Clinical therapeutics vol. 39 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin. [electronic resource] by Fazio, Sergio Robertson, David G Joh, Tenshang Wan, Hong Riel, Tom Forgues, Philippe Baum, Charles M Garzone, Pamela D Gumbiner, Barry Producer: 20180827 In: Cardiovascular therapeutics vol. 36 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. [electronic resource] by Gumbiner, Barry Joh, Tenshang Liang, Hong Wan, Hong Levisetti, Matteo Vana, Alicia M Shelton, David L Forgues, Philippe Billotte, Stephan Pons, Jaume Baum, Charles M Garzone, Pamela D Producer: 20180827 In: Cardiovascular therapeutics vol. 36 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)